- Storaktionærmeddelelse - Pharma Equity Group A/S
- Major shareholder announcement - Pharma Equity Group A/S
- Forløb af generalforsamlingen i Pharma Equity Group A/S
- Passing of the General Meeting of Pharma Equity Group A/S
- Bestyrelsens beslutning om udstedelse af konvertible lån
- The Board of Director's decision to issue convertible loans
- Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
- Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, rapporterer meget positive slutresultater fra det klinisk fase-2 studie med selskabets patenterede lægemiddelkandidat RNX-051.
- Notice convening the annual general meeting in Pharma Equity Group A/S
- Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S
More ▼
Key statistics
On Monday, Pharma Equity Group A/S (PEG:CPH) closed at 0.24, 3.45% above its 52-week low of 0.232, set on Apr 30, 2024.
52-week range
Open | 0.247 |
---|---|
High | 0.248 |
Low | 0.238 |
Bid | 0.238 |
Offer | 0.24 |
Previous close | 0.249 |
Average volume | 372.14k |
---|---|
Shares outstanding | 1.02bn |
Free float | 1.01bn |
P/E (TTM) | -- |
Market cap | 254.72m DKK |
EPS (TTM) | -0.0234 DKK |
Data delayed at least 15 minutes, as of May 06 2024 16:10 BST.
More ▼